Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05LKO
|
||||
| Former ID |
DNC006813
|
||||
| Drug Name |
1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [528224] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H24N2O
|
||||
| Canonical SMILES |
COC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3
|
||||
| InChI |
1S/C19H24N2O/c1-22-19-10-6-5-9-17(19)15-18(16-7-3-2-4-8-16)21-13-11-20-12-14-21/h2-10,18,20H,11-15H2,1H3
|
||||
| InChIKey |
PFTJCYRHNKTTTO-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent serotonin transporter | Target Info | Inhibitor | [530918] | |
| Sodium-dependent dopamine transporter | Target Info | Inhibitor | [528224] | ||
| Sodium-dependent noradrenaline transporter | Target Info | Inhibitor | [530918] | ||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | 5HT1 type receptor mediated signaling pathway | ||||
| 5HT2 type receptor mediated signaling pathway | |||||
| 5HT3 type receptor mediated signaling pathway | |||||
| 5HT4 type receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis | |||||
| Parkinson disease | |||||
| Dopamine receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis | |||||
| Pathway Interaction Database | Alpha-synuclein signaling | ||||
| WikiPathways | Monoamine Transport | ||||
| SIDS Susceptibility Pathways | |||||
| NRF2 pathway | |||||
| Synaptic Vesicle Pathway | |||||
| Serotonin Transporter ActivityWP727:Monoamine Transport | |||||
| Dopaminergic Neurogenesis | |||||
| Parkinsons Disease Pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
| Neurotransmitter Clearance In The Synaptic CleftWP727:Monoamine Transport | |||||
| References | |||||
| Ref 528224 | Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. Epub 2006 Jun 5.N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. | ||||
| Ref 530918 | Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. Epub 2010 Apr 18.Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.